Urispas and Back pain - a phase IV clinical study of FDA data

Summary:

Back pain is reported as a side effect among people who take Urispas (flavoxate hydrochloride), especially for people who are female, 60+ old, also take Synthroid, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Back pain when taking Urispas. It is created by eHealthMe based on reports of 590 people who have side effects when taking Urispas from the FDA, and is updated regularly.

What is Urispas?

Urispas has active ingredients of flavoxate hydrochloride. eHealthMe is studying from 598 Urispas users. Check the latest studies of Urispas.

What is Back pain?

Back pain is found to be associated with 3,199 drugs and 4,716 conditions by eHealthMe. Check the latest studies of Back pain.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 28, 2026

590 people reported to have side effects when taking Urispas.
Among them, 19 people (3.22%) have Back pain.

Among these 19 people:

What is the gender of people who have Back pain when taking Urispas? *

female: 94.12 %
male: 5.88 %

What is the age of people who have Back pain when taking Urispas? *

What are other drugs people take besides Urispas? *

What are other side effects people have besides Back pain? *

Anaemia (lack of blood): 17 people, 89.47%
Joint Pain: 17 people, 89.47%
Drug Ineffective: 17 people, 89.47%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 16 people, 84.21%
Joint Swelling: 16 people, 84.21%
C-Reactive Protein Abnormal: 16 people, 84.21%
Oral Pain: 16 people, 84.21%
Peripheral Swelling: 16 people, 84.21%
Pneumonia Viral: 16 people, 84.21%
C-Reactive Protein Increased: 16 people, 84.21%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 16 people, 84.21%
Joint Pain: 12 people, 63.16%
Pain: 7 people, 36.84%
Neuropathy Peripheral (surface nerve damage): 1 person, 5.26%
Nervous System Disorder (a general class of medical conditions affecting the nervous system): 1 person, 5.26%
Gastric Disorder (disease of stomach): 1 person, 5.26%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 5.26%
Blood Potassium Decreased: 1 person, 5.26%
Bladder Disorder: 1 person, 5.26%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Urispas and have Back pain?

- Check whether Back pain is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Urispas:

Urispas (598 reports)

Back pain treatments and more:

Back pain (379,875 reports)

Browse all side effects of Urispas:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Back pain:

Back pain (3,199 drugs)

Browse all the conditions that are associated with Back pain:

Back pain (4,716 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on flavoxate hydrochloride (the active ingredients of Urispas) and Urispas (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.